7539-30-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1-(4-methoxyphenyl)-N-(2-nitrobenzyl)methanamine is used as a compound in pharmaceutical research and drug development for its potential medicinal properties. 1-(4-methoxyphenyl)-N-(2-nitrobenzyl)methanamine's unique structure may contribute to the treatment of various diseases and disorders, although further research is required to understand its full biological effects and potential applications.
Used in Chemical Synthesis:
In the chemical industry, 1-(4-methoxyphenyl)-N-(2-nitrobenzyl)methanamine may be used as a building block or intermediate in the synthesis of more complex molecules with specific applications in various fields, including pharmaceuticals, materials science, and agrochemicals.

Upstream product

• 2393-23-9 4-methoxy-benzylamine 
• 552-89-6 2-nitro-benzaldehyde 
• 3958-60-9 2-nitrophenylmethyl bromide 

Relevant academic research and scientific papers

Hydroboration and reductive amination of ketones and aldehydes with HBpin by a bench stable Pd(ii)-catalyst

A palladium(ii) complex [(κ4-{1,2-C6H4(NCH-C6H4O)2}Pd] (1) supported by a dianionic salen ligand [1,2-C6H4(NCH-C6H4O)2]2- (L) was synthesised and used as a molecular pre-catalyst in the hydroboration of aldehydes and ketones. The molecular structure of Pd(ii) complex 1 was established by single-crystal X-ray diffraction analysis. Complex 1 was tested as a competent pre-catalyst in the hydroboration of aldehydes and ketones with pinacolborane (HBpin) to produce corresponding boronate esters in excellent yields at ambient temperature under solvent-free conditions. Further, the complex 1 proved to be a competent catalyst in the reductive amination of aldehydes with HBpin and primary amines under mild and solvent-free conditions to afford a high yield (up to 97%) of corresponding secondary amines. Both protocols provided high conversion, superior selectivity and broad substrate scope, from electron-withdrawing to electron-donating and heterocyclic substitutions. A computational study based on density functional theory (DFT) revealed a reaction mechanism for Pd-catalysed hydroboration of carbonyl species in the presence of HBpin. The protocols also uncovered the dual role of HBpin in achieving the hydroboration reaction.

Catalytic Hydroboration and Reductive Amination of Carbonyl Compounds by HBpin using a Zinc Promoter

The chemoselective hydroboration of aldehydes and ketones, catalyzed by Zinc(II) complexes [κ2-(PyCH=NR)ZnX2] [R=CPh3, X=Cl (1) and R=Dipp (2,6-diisoropylphenyl) and X=I (2)], in the presence of pinacolborane (HBpin) at ambient temperature and under solvent-free conditions, which produced the corresponding boronate esters in high yield, is reported. Zinc metal complexes 1 and 2 were derived in 80–90% yield from the reaction of iminopyridine [PyCH=NR] with anhydrous zinc dichloride in dichloromethane at room temperature. The solid-state structures of both zinc complexes were confirmed using X-ray crystallography. Zinc complex 1 was also used as a competent pre-catalyst in the reductive amination of carbonyl compounds with HBpin under mild and solvent-free conditions to afford a high yield (up to 97%) of the corresponding secondary amines. The wider substrate scope of both reactions was explored. Catalytic protocols using zinc as a pre-catalyst demonstrated an atom-economic and green method with diverse substrates bearing excellent functional group tolerance. Computational studies established a plausible mechanism for catalytic hydroboration.

Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for α-synuclein fibrils by SPR evaluation system

PET imaging of α-synuclein (α-syn) deposition in the brain will be an effective tool for earlier diagnosis of Parkinson's disease (PD) due to α-syn aggregation is the widely accepted biomarker for PD. However, the necessary PET radiotracer for imaging is clinically unavailable until now. The lead compound discovery is the first key step for the study. Herein, we initially established an efficient biologically evaluation system well in high throughput based on SPR technology, and identified a novel class of N, N-dibenzylcinnamamide (DBC) compounds as α-syn ligands through the assay. These compounds were proved to have high affinities against α-syn aggregates (KD D) has been acquired, indicating its potential as a new lead compound for developing PET radiotracer.

Compound capable of being strongly bound with alpha-synuclein aggregate, and preparation method and use of compound

The invention belongs to the technical field of medicine, and relates to a compound with a structural general formula I, and a preparation method and use of the compound. In the formula I, R1 is selected from phenyl, substituted phenyl, pyridyl and pyrimidinyl, and i is selected from 0 to 2, and is an integer; R2 is selected from alkyl, phenyl, substituted phenyl and 5-6-membered aromatic heterocyclic rings, and m is selected from 0 to 5, and is an integer; and R3 is selected from phenyl and substituted phenyl, and n is selected from 0 to 3, and is an integer. The compound comprises a cis-isomer, a trans-isomer or a mixture of the cis-isomer and the trans-isomer of the compound with the formula I structure. The compound can be strongly bound to an alpha-synuclein aggregate, can be used asan imaging tracer for the image technology such as PET, SPECT and the like, or can be used for preparing an imaging tracer and a composition containing the imaging tracer, the compound can be used forparticularly detecting Parkinson's disease or neurological disorders associated with the misfolding and aggregation of alpha-synuclein, and the compound has very good application prospects.

N,N-bond-forming heterocyclization: Synthesis of 3-alkoxy-2H-indazoles

A one-step heterocyclization of o-nitrobenzylamines to 3-alkoxy-2H- indazoles is reported. The electronic nature of the nitrophenyl group, the steric and electronic nature of the R1-functionalized benzylic amine, and the nature of the alcoholic solvent affect the efficiency of this heterocyclization reaction (～40-90%).